Septerna

Edit info

Founded: 2021

Location: South SF, CA

Employee range: 0 - 0

Clinical stage: Clin0

Therapy area: Hypoparathyroidism

Drug types: END, IMM, OPH, NEU, PN

Lead product: Undisclosed

Funding: $150M B Jul 2023; $100M A Jan 2022

Investors: Third Rock Ventures, Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital, Logos Capital, RA Capital Management, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Driehaus Capital Management, Woodline Partners LP, Soleus Capital

septerna.com

linkedin.com

job board

Drug notes:

Undisclosed Clin0 Grave's disease, thyroid eye disease; 3 CNS disorders, inflammatory & pain disorders, undisclosed

About:

Septerna is developing drugs against G-protein coupled receptors (GPCRs). GPCRs are found at the cell membrane and have proven to be the most ‘druggable’ class of proteins. However, many remain ‘undruggable’. Septerna is addressing this problem using their Native Complex platform to design a new era of GPCR-targeted medicines. The platform recapitulates the native structure, function and dynamics of GPCRs, thus enabling structure-based drug design and large-scale screening. Drug hits are further examined with Cryo-EM and optimized through in silico approaches. Due to the prolific nature of GPCRs, Septerna’s diversified portfolio spans multiple therapeutic areas.